Modelling the role of dual specificity phosphatases in Herceptin resistant breast cancer cell lines

BACKGROUND Breast cancer remains the most lethal type of cancer for women. A significant proportion of breast cancer cases are characterised by overexpression of the human epidermal growth factor receptor 2 protein (HER2). These cancers are commonly treated by Herceptin (Trastuzumab), but resistance to drug treatment frequently develops in tumour cells. Dual-specificity phosphatases (DUSPs) are thought to play a role in the mechanism of resistance, since some of them were reported to be overexpressed in tumours resistant to Herceptin. RESULTS We used a systems biology approach to investigate how DUSP overexpression could favour cell proliferation and to predict how this mechanism could be reversed by targeted inhibition of selected DUSPs. We measured the expression of 20 DUSP genes in two breast cancer cell lines following long-term (6 months) exposure to Herceptin, after confirming that these cells had become resistant to the drug. We constructed several Boolean models including specific substrates of each DUSP, and showed that our models correctly account for resistance when overexpressed DUSPs were kept activated. We then simulated inhibition of both individual and combinations of DUSPs, and determined conditions under which the resistance could be reversed. CONCLUSIONS These results show how a combination of experimental analysis and modelling help to understand cell survival mechanisms in breast cancer tumours, and crucially enable us to generate testable predictions potentially leading to new treatments of resistant tumours.

[1]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[2]  Andre T Baron,et al.  Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells. , 2009, Cancer research.

[3]  Luiz Eduardo Soares de Oliveira,et al.  A Dataset for Breast Cancer Histopathological Image Classification , 2016, IEEE Transactions on Biomedical Engineering.

[4]  M. Sliwkowski,et al.  Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer. , 2014, Biochimica et biophysica acta.

[5]  Joanna M. Sasin,et al.  Protein Tyrosine Phosphatases in the Human Genome , 2004, Cell.

[6]  J. Budczies,et al.  DUSP4 is associated with increased resistance against anti-HER2 therapy in breast cancer , 2017, Oncotarget.

[7]  Lei Wang,et al.  Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R , 2014, BMC Cancer.

[8]  R. Finn,et al.  Current approaches and future directions in the treatment of HER2-positive breast cancer. , 2013, Cancer treatment reviews.

[9]  E. Nishida,et al.  Regulation of MAP kinases by MAP kinase phosphatases. , 2007, Biochimica et biophysica acta.

[10]  R. Nahta,et al.  Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer , 2008, Molecular Cancer Therapeutics.

[11]  S. Keyse,et al.  The regulation of oncogenic Ras/ERK signalling by dual-specificity mitogen activated protein kinase phosphatases (MKPs) , 2016, Seminars in cell & developmental biology.

[12]  Y. Yarden,et al.  The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand‐receptor interactions , 1997, FEBS letters.

[13]  Hsien-yu Wang,et al.  Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer. , 2003, Cancer letters.

[14]  I. Bahar,et al.  Structurally Unique Inhibitors of Human Mitogen-Activated Protein Kinase Phosphatase-1 Identified in a Pyrrole Carboxamide Library , 2007, Journal of Pharmacology and Experimental Therapeutics.

[15]  J. Settleman,et al.  Targeting the RAF-MEK-ERK pathway in cancer therapy. , 2009, Cancer letters.

[16]  F. Claret,et al.  Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer , 2012, Front. Oncol..

[17]  Maido Remm,et al.  Enhancements and modifications of primer design program Primer3 , 2007, Bioinform..

[18]  P. Lazo.  Emerging signaling pathways in tumor biology , 2010 .

[19]  Carlos L. Arteaga,et al.  Treatment of HER2-positive breast cancer: current status and future perspectives , 2012, Nature Reviews Clinical Oncology.

[20]  Ting-ting Zhou,et al.  Network systems biology for targeted cancer therapies , 2012, Chinese journal of cancer.

[21]  Tim Beißbarth,et al.  Boolean ErbB network reconstructions and perturbation simulations reveal individual drug response in different breast cancer cell lines , 2014, BMC Systems Biology.

[22]  B. Faircloth,et al.  Primer3—new capabilities and interfaces , 2012, Nucleic acids research.

[23]  Tim Beißbarth,et al.  mRNA Profiling Reveals Determinants of Trastuzumab Efficiency in HER2-Positive Breast Cancer , 2015, PloS one.

[24]  J. Schwartz,et al.  Dynamics of DNA Damage Induced Pathways to Cancer , 2012, PloS one.

[25]  M. Arbushites,et al.  Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  C. Ji,et al.  Molecular cloning and characterization of a novel dual-specificity phosphatase 23 gene from human fetal brain. , 2004, The international journal of biochemistry & cell biology.

[27]  M. Loda,et al.  Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis. , 1996, The American journal of pathology.

[28]  Xuelin Huang,et al.  An improvement of the 2ˆ(-delta delta CT) method for quantitative real-time polymerase chain reaction data analysis. , 2013, Biostatistics, bioinformatics and biomathematics.

[29]  Holger Fröhlich,et al.  Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance , 2009, BMC Systems Biology.

[30]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[31]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[32]  L. Tabernero,et al.  Dual-specificity MAP kinase phosphatases as targets of cancer treatment. , 2011, Anti-cancer agents in medicinal chemistry.

[33]  Kelly K. Haagenson,et al.  The role of MAP kinases and MAP kinase phosphatase-1 in resistance to breast cancer treatment , 2010, Cancer and Metastasis Reviews.

[34]  Valerie Speirs,et al.  Choosing the right cell line for breast cancer research , 2011, Breast Cancer Research.

[35]  S. Hurvitz,et al.  Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates. , 2014, Annals of translational medicine.

[36]  Naoto T. Ueno,et al.  P27kip1 Down-Regulation Is Associated with Trastuzumab Resistance in Breast Cancer Cells , 2004, Cancer Research.

[37]  Y. Yarden,et al.  The basic biology of HER2. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  S. Hilsenbeck,et al.  Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers -- role of estrogen receptor and HER2 reactivation , 2011, Breast Cancer Research.

[39]  K. Takagaki,et al.  Characterization of a novel low-molecular-mass dual-specificity phosphatase-3 (LDP-3) that enhances activation of JNK and p38. , 2004, The Biochemical journal.

[40]  J. Svaren,et al.  Dual specificity phosphatase 15 regulates Erk activation in Schwann cells , 2017, Journal of neurochemistry.

[41]  Jean-Marc Schwartz,et al.  Regulation of dual specificity phosphatases in breast cancer during initial treatment with Herceptin: a Boolean model analysis , 2018, BMC Systems Biology.

[42]  H. Gautrey,et al.  The HER2 Signaling Network in Breast Cancer—Like a Spider in its Web , 2014, Journal of Mammary Gland Biology and Neoplasia.

[43]  Andreas Vogt,et al.  The Benzo[c]phenanthridine Alkaloid, Sanguinarine, Is a Selective, Cell-active Inhibitor of Mitogen-activated Protein Kinase Phosphatase-1* , 2005, Journal of Biological Chemistry.

[44]  J. Woodgett,et al.  The stress activated protein kinase pathway. , 1996, Cancer surveys.

[45]  S. Keyse,et al.  Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases , 2007, Oncogene.

[46]  J. Rüschoff,et al.  HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer , 2014, Cell Death and Disease.

[47]  A. Sapino,et al.  HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib , 2011, Breast Cancer Research and Treatment.